Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul|||0000-0002-5926-8437
  • Gervais, A.
  • Taniguchi, M.
  • Saare, L.
  • Särekannu, K.
  • Voyer, T.L.
  • Philippot, Q.
  • Rosain, J.
  • Bizien, L.
  • Asano, T.
  • Garcia-Prat, Marina|||0000-0001-5387-1908
  • Parra-Martínez, Alba|||0000-0002-9564-8912
  • Migaud, M.
  • Tsumura, M.
  • Conti, F.
  • Belot, Alexandre|||0000-0003-4902-5332
  • Rivière, Jacques G.|||0000-0003-1055-2063
  • Morio, T.
  • Tanaka, J.
  • Javouhey, E.
  • Haerynck, F.
  • Duvlis, S.
  • Ozcelik, Tayfun|||0000-0001-5937-1082
  • Keles, S.
  • Tandjaoui-Lambiotte, Y.
  • Escoda, S.
  • Husain, M.
  • Pan-Hammarström, Q.
  • Hammarström, L.
  • Ahlijah, G.
  • Haidar, A.A.
  • Soudee, C.
  • Arseguel, V.
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Sahanic, S.
  • Tancevski, I.
  • Nukui, Y.
  • Hayakawa, S.
  • Chrousos, G.P.
  • Michos, A.
  • Tatsi, E.B.
  • Filippatos, F.
  • Rodriguez-Palmero, A.
  • Troya, Jesús|||0000-0001-7323-114X
  • Tipu, I.
  • Meyts, I.
  • Roussel, L.
  • Ostrowski, S.R.
  • Schidlowski, L.
  • Prando, C.
  • Condino-Neto, Antonio|||0000-0002-1069-3117
  • Cheikh, N.
  • Bousfiha, A.A.
  • Bakkouri, J.E.
  • Peterson, P.
  • Pujol, Aurora|||0000-0002-9606-0600
  • Lévy, R.
  • Quartier, P.
  • Vinh, D.C.
  • Boisson, Bertrand|||0000-0001-5240-3555
  • Béziat, V.
  • Zhang, S.Y.
  • Borghesi, A.
  • Pession, A.
  • Andreakos, E.
  • Marr, N.
  • Mentis, A.F.A.
  • H.mogensen, T.
  • Rodríguez-Gallego, C.
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Tillmann, V.
  • Neven, B.
  • Trouillet-Assant, S.
  • Brodin, P.
  • Abel, Laurent|||0000-0001-7016-6493
  • Jouanguy, Emmanuelle|||0000-0002-7358-9157
  • Zhang, Q.
  • Martinón Torres, Federico|||0000-0002-9023-581X
  • Salas, A.
  • Gómez-Carballa, A.
  • Gonzalez-Granado, L.I.
  • Kisand, K.
  • Okada, S.
  • Puel, A.
  • Cobat, Aurélie|||0000-0001-7209-6257
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • AlKhater, Suzan|||0000-0001-7315-6581
  • Alkan, G.
  • Castagnoli, R.
  • Cyrus, C.|||0000-0001-7333-6486
  • Bozdemir, S.E.
  • Emiroglu, M.
  • Gulhan, Belgin|||0000-0003-0839-1301
  • Erdeniz, E.H.
  • Hatipoglu, N.
  • Bayhan, G.I.|||0000-0002-1423-4348
  • Jabandziev, P.
  • Yuksek, S.K.
  • Karbuz, A.
  • Öz, Ş.K.T.
  • Marseglia, G.L.
  • Akcan, O.M.
  • Kılıç, A.O.
  • Parlakay, A.O.
  • Papadaki, M.
  • Slaba, K.
  • Sevketoglu, Esra|||0000-0002-8330-2877
  • Valencia-Ramos, J.
  • Yahşi, A.
  • Tuala, C.
  • Urbieta, A.I.D.
  • Esteban, B.D.
  • Santalla, M.J.D.
  • Pérez, C.F.
  • Villaverde, J.F.
  • Rodríguez, C.G.
  • Allut, J.L.G.
  • Vicente, L.G.
  • Vázquez, E.G.
  • Carballa, A.G.
  • Rial, J.G.
  • Barcala, F.J.G.
  • Liñares, B.G.
  • Iglesias, P.L.
  • Massa, B.L.
  • Fuentes, M.L.
  • Franco, M.L.
  • Lago, A.L.
  • Cruz, D.N.D.l
  • Masid, E.N.
  • Devesa, J.B.O.
  • Seco, J.P.
  • Núñez, M.P.
  • Bernal, M.P.D.M.
  • Freixo, H.P.
  • Rodríguez, L.P.
  • Pischedda, S.
  • Romero, M.P.
  • Reino, A.P.
  • Hervella, G.M.P.
  • Verdes, T.Q.
  • Redondo Collazo, Lorenzo|||0000-0002-3521-678X
  • Casuso, P.R.
  • García, S.R.
  • Vázquez, S.R.
  • Blanco, V.R.
  • Calle, I.R.
  • Velasco, C.R.
  • Núñez, N.R.
  • Sánchez, C.R.T.
  • Paz, E.S.
  • Orayyou, J.M.S.
  • Villanueva, C.S.
  • Fernández, S.S.
  • Sanmartín, P.S.
  • Muñiz, M.T.
  • Pena, R.T.
  • Castellano, M.T.
  • Cuadrado, L.V.
  • García, P.V.
  • Iglesias, M.S.V.
  • Lasheras, S.V.
  • Ferreiro Iglesias, Rocío|||0000-0002-0469-4332
  • Bastón-Rey, I.
  • Calviño-Suárez, C.
  • Aiuti, Alessandro|||0000-0002-5398-1717
  • Al-Muhsen, S.
  • Al-Mulla, F.
  • Amara, A.
  • Anderson, M.S.
  • Arias, A.A.
  • Arkin, L.M.
  • Feldman, H.B.
  • Biggs, C.M.
  • Bogunovic, Dusan|||0000-0002-9277-3232
  • Bolze, Alexandre|||0000-0001-7399-2766
  • Bondarenko, A.|||0000-0002-9737-2868
  • Bryceson, Y.
  • Butte, M.J.
  • Casari, G.
  • Christodoulou, J.
  • Constantinescu, S.N.
  • Cooper, M.A.
  • Dalgard, C.L.
  • Desai, M.
  • Drolet, B.A.
  • Duval, X.
  • Baghdadi, J.E.
  • Eloy, P.
  • Espinosa-Padilla, S.
  • Fellay, Jacques|||0000-0002-8240-939X
  • Flores, Carlos|||0000-0001-5352-069X
  • Franco, J.L.
  • Froidure, A.
  • Gorochov, G.
  • Gregersen, P.K.
  • Grimbacher, B.
  • Hagin, D.
  • Halwani, R.
  • Heath, J.R.
  • Hsieh, E.W.Y.
  • Husebye, Eystein Sverre|||0000-0002-7886-2976
  • Imai, K.
  • Itan, Yuval
  • Jarvis, E.D.
  • Kaja, E.
  • Karamitros, T.
  • Ku, C.L.
  • Lau, Y.L.
  • Ling, Y.
  • Lucas, C.L.
  • Mansouri, D.
  • Maródi, L.
  • Mentré, F.
  • Milner, J.D.
  • Mironska, K.
  • Mogensen, T.H.
  • Ng, L.F.P.
  • Notarangelo, L.D.
  • Novelli, A.
  • Novelli, G.
  • O'Farrelly, C.
  • Okamoto, K.
  • Pape, J.W.
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Perez-Tur, J.
  • Perlin, D.S.
  • Pesole, G.
  • Planas, A.M.
  • Quintana-Murci, L.
  • Ramaswamy, S.
  • Renia, L.
  • Resnick, I.
  • Sancho-Shimizu, V.
  • Sediva, A.
  • Seppänen, M.R.J.
  • Shahrooei, M.
  • Shcherbina, A.
  • Slaby, O.
  • Snow, A.L.
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Soumelis, V.
  • Spaan, A.N.
  • Su, H.C.
  • Tangye, S.G.
  • Tayoun, A.A.
  • Temel, Ş.G.
  • Thorball, C.
  • Tiberghien, P.
  • Turvey, S.E.
  • Uddin, K.M.F.
  • Uddin, M.J.
  • Beek, D.v.d
  • Bernuth, H.v
  • Wauters, J.
  • Zatz, Mayana|||0000-0003-3970-8025
  • Zawadzki, Pawel
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7-9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2-5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6-35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1-9.6]) of IFN-ω and/or IFN-α2.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Respiratory syncytial virus–related lower respiratory tract infection hospitalizations in infants receiving nirsevimab in Galicia (Spain): the NIRSE‑GAL study

  • Manzanares, Ángela
  • Pardo Seco, Jacobo José
  • Rivero Calle, Irene
  • Dacosta Urbieta, Ana Isabel
  • Mallah, Narmeen
  • Rodríguez-Tenreiro Sánchez, Carmen
  • Salas Ellacuriaga, Antonio
  • Martinón Torres, Federico
As part of the NIRSEGAL study (https://www.nirsegal.es/en), we present the clinical characteristics and course of respiratory syncytial virus (RSV)-related low respiratory tract infection (LRTI) hospitalizations in infants eligible for nirsevimab administration during the 2023–2024 season. Infants eligible for nirsevimab immunization (born between 1 April, 2023, and 30 March, 2024) who were hospitalized due to RSV-related LRTI between September 25, 2023, and April 15, 2024, in a hospital from the Galician Public Health system were included. Clinical and demographic characteristics of RSV-related LRTI hospitalizations were analyzed, with comparisons made between breakthrough cases (those immunized with nirsevimab) and non-breakthrough cases. During the study period, 69 RSV-related LRTI hospitalizations were recorded, with a median hospital stay of 4 (interquartile range (IQR) 3–6) days; 65.2% (N=45) were breakthrough cases. The median age was 2.7 (IQR 1.5–5.2) months, and more than half of them (N=39, 56.5%) were male. The incidence of cases was parallel to the RSV epidemic curve, suggesting no waning of nirsevimab efcacy. Of the total hospitalizations, 16 infants (23.2%) had a high-risk condition, 44 (63.8%) needed oxygen support, 15 (21.7%) were admitted to the intensive care unit (ICU), and 11 (15.9%) received non-invasive mechanical ventilation (NIMV). No statistically signifcant diferences were observed in these characteristics when comparing breakthrough and non-breakthrough cases. Conclusion: In the nirsevimab era, a substantial proportion of children who were hospitalized for RSV-related LRTI needed oxygen support, NIMV, and ICU admission. Clinical characteristics, timing, and outcomes were comparable between breakthrough and non-breakthrough cases. Trial registration: The NIRSE-GAL study protocol was registered on ClinicalTrials.gov (NCT06180993).